Search Results

Direct osmotic concentration (DOC) is an integrated membrane treatment process designed for the reclamation of spacecraft wastewater. The system includes forward osmosis (FO), membrane evaporation, reverse osmosis (RO) and an aqueous phase catalytic oxidation (APCO) post-treatment unit. This document describes progress in the third year of a four year project to advance hardware maturity of this technology to a level appropriate for human rated testing. The current status of construction and testing of the final deliverable is covered and preliminary calculations of equivalent system mass are funished.

NASA is currently developing two new human rated launch systems. They are the Crew Exploration Vehicle (CEV) and the Lunar Surface Access Module (LSAM). Both of these spacecraft will require new life support systems to support the crew. These life support systems can also be designed to reduce the mass required to keep humans alive in space. Water accounts for about 80% of the mass required to keep a person alive. As a result recycling water offers a high return on investment. Recycling water can also increase mission safety by providing an emergency supply of drinking water. This paper evaluates the potential benefits of two wastewater treatment technologies that have been designed to reduce the mass of the CEV and LSAM missions. For a 3 day CEV mission to the International Space Station (ISS) this approach could reduce the mass required to provide drinking water by 65% when compared to stored water. For an 18 day Lunar mission a mass savings of 70% is possible.

Direct osmotic concentration (DOC) has been identified as a potential wastewater treatment process for potable reuse in advanced life support systems (ALSS). As a result, further development of the DOC process is being supported by a NASA Rapid Technology Development Team (RTDT) program. DOC is an integrated membrane system combining three unique membrane separation processes including forward osmosis (FO), membrane distillation (MD), and reverse osmosis (RO) that is designed to treat separate wastewater streams comprising hygiene wastewater, humidity condensate, and urine. An aqueous phase catalytic oxidation (APCO) process is incorporated as post treatment for the product water. In an ongoing effort to improve the DOC process and make it fully autonomous, further development of the three membrane technologies is being pursued.

This study introduces new concepts in the function and placement of membrane based water treatment processes in Exploration Life Support (ELS) System design. These differences are in both form and function and have the potential to radically alter the current paradigms of thought within the ELS research community with regards to the limitations of conventional membrane water treatment. More importantly, they have the potential to change the placement of water processing by quite literally moving it “out of the box”, or in the case of ELS, the standard rack volume. Two possible systems, extremely small scale personal urine treatment and recycle (CEV Lightweight Contingency Water Treatment) and a similar but scaled up habitat wall embedded membrane water treatment pouch, are used to demonstrate the concepts involved.

The Lightweight Contingency Water Recovery System (LWC-WRS) harvests water from various sources in or around the Orion spacecraft in order to provide contingency water at a substantial mass savings when compared to stored emergency water supplies. The system uses activated carbon treatment (for urine) followed by forward osmosis (FO). The LWC-WRS recovers water from a variety of contaminated sources by directly processing it into a fortified (electrolyte and caloric) drink. Primary target water sources are urine, seawater, and other on board vehicle waters (often referred to as technical waters). The product drink provides hydration, electrolytes, and caloric requirements for crew consumption. The system hardware consists of a urine collection device containing an activated carbon matrix (Stage 1) and an FO membrane treatment element (or bag) which contains an internally mounted cellulose triacetate membrane (Stage 2).